CALL FOR PAPERS

EUROPEAN PHARMACEUTICAL LAW REVIEW (EPLR)

4 issues/year · approx. 70 pages · 2511-7157 · print and online · www.lexxion.eu/zeitschriften/eplr/

EUROPEAN PHARMACEUTICAL LAW REVIEW (EPLR)

The European Pharmaceutical Law Review (EPLR) is the one-stop forum for analysis of pharmaceutical law and policy developments in the EU and its Member States. Offering an in-depth lead article, country and thematic reports, case notes and an overview of legal regulatory developments, the EPLR is a must read for both practitioners and academics.

Contributors to the journal report on key legislative developments in the EU and the Member States, and identify and analyse important judgments that shape the interpretation and application of EU pharmaceutical law. For the issues of EPLR we welcome submissions of articles, country or policy reports and case annotations on, but not limited to, the following topics:

- pharmaceutical law and policy (regional, national, international);
- Commission decisions (EMA opinions) and regulatory guidelines;
- national EU, and International Jurisprudence;
- medical devices;
- borderline cases: pharmaceuticals/food/cosmetics/chemicals
- patents/trademarks
- health technology assessment and pricing/reimbursement
- digital health/big data

All contributions will be subject to double blind peer-review before acceptance for publication and are required to conform to the author guidelines available at: www.lexxion.eu/eplr/#authors

Submission Deadlines:

- Issue 2/2021 15 March 2021
- Issue 3/2021 15 June 2021
- Issue 4/2021 1 October 2021

Send submissions to:

Jakob McKernan
Executive Editor
mckernan@lexxion.eu
+49-30-81 45 06-10

SEND SUBMISSIONS TO:
Jakob McKernan
Executive Editor
mckernan@lexxion.eu
+49-30-81 45 06-10